ClinicalTrials.gg
CompletedNCT04590937Updated Sep 6, 2023Results posted

A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body

A Phase 1 interventional study of BI 730357 and CRESTOR® in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the effect of BI 730357 under steady state conditions on the pharmacokinetics of digoxin, furosemide, metformin and rosuvastatin given as a cocktail (Reference, R: cocktail alone; Test T: cocktail given under steady state conditions of BI 730357).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead (ECG), and clinical laboratory Tests
  • Age of 18 to 55 years (inclusive)
  • of 18.5 to 29.9 kilogram per square meter (kg/m2) (inclusive)
  • Signed and dated written prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation
  • Male subjects, or female subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion: -- Use of adequate , e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives, intrauterine device

    • Sexually abstinent
    • A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
    • Surgically sterilised (including hysterectomy or bilateral tubal occlusion)
    • , defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with levels of Follicle-stimulating hormone (FSH) above 40 units per liter (U/L) and estradiol below 30 nanograms per liter (ng/L) is confirmatory)

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetres of Mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • During COVID-19 pandemic: laboratory test indicative of an ongoing SARS-CoV-2 infection
  • further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Cocktail/ Cocktail + BI 730357

    Cocktail treatment will be followed by the Test treatment in a fixed sequence. The treatment periods are separated by a wash-out phase of at least 14 days between the two cocktail administrations.

    Drug: BI 730357 · Drug: CRESTOR® · Drug: Lenoxin® · Drug: MetfoLiquid GeriaSan® · Drug: Lasix®

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin)

    Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  2. Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Rosuvastatin)

    Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  3. Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Furosemide)

    Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  4. Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Digoxin)

    Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  5. Maximum Measured Concentration of Metformin in Plasma (Cmax, Metformin)

    Maximum measured concentration of Metformin in plasma is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  6. Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax, Rosuvastatin)

    Maximum measured concentration of Rosuvastatin in plasma is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  7. Maximum Measured Concentration of Furosemide in Plasma (Cmax, Furosemide)

    Maximum measured concentration of Furosemide in plasma is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  8. Maximum Measured Concentration of Digoxin in Plasma (Cmax, Digoxin)

    Maximum measured concentration of Digoxin in plasma is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Metformin)

    Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  2. Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Rosuvastatin)

    Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  3. Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Furosemide)

    Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

  4. Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Digoxin)

    Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

    Time frame: 2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.

07

Results

Posted Jul 17, 2023

Participant flow

This open-label, non-randomised, 2-period fixed-sequence trial in healthy subjects was to test whether BI 730357 affects how 4 other medicines (rosuvastatin, digoxin, metformin, and furosemide) are taken up in the body.

Period 1 - Cocktail
Participant flow — Period 1 - Cocktail
MilestoneCocktail (R) / BI 730357+Cocktail (T)
Started15
Completed15
Not completed0
Period 2 - BI 730357+Cocktail
Participant flow — Period 2 - BI 730357+Cocktail
MilestoneCocktail (R) / BI 730357+Cocktail (T)
Started15
Treated at least one dose of bi15
Treated at least one dose of cocktail+bi14
Completed14
Not completed1
Withdrew: Covid-19 related1

Outcome measures

PrimaryArea Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin)

Area under the concentration-time curve of Metformin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin)
hour * nanomole / liter (h*nmol/L)Metformin (Period 1)Metformin + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin)1460.83 ± NA1434.81 ± NA
Statistical analysis
  • Metformin (Period 1) vs Metformin + BI 730357 (Period 2) · Geometric means ratio: 98.22 · 90% CI 94.89 to 101.67The geometric means ratio was calculated as Metformin + BI 730357 / Metformin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryArea Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Rosuvastatin)

Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Rosuvastatin)
hour * nanomole / liter (h*nmol/L)Rosuvastatin (Period 1)Rosuvastatin + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Rosuvastatin)90.08 ± NA110.87 ± NA
Statistical analysis
  • Rosuvastatin (Period 1) vs Rosuvastatin + BI 730357 (Period 2) · Geometric means ratio: 123.08 · 90% CI 112.22 to 134.98The geometric means ratio was calculated as Rosuvastatin + BI 730357 / Rosuvastatin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryArea Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Furosemide)

Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Furosemide)
hour * nanomole / liter (h*nmol/L)Furosemide (Period 1)Furosemide + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Furosemide)157.57 ± NA185.50 ± NA
Statistical analysis
  • Furosemide (Period 1) vs Furosemide + BI 730357 (Period 2) · Geometric means ratio: 117.72 · 90% CI 110.57 to 125.34The geometric means ratio was calculated as Furosemide + BI 730357 / Furosemide. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryArea Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Digoxin)

Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 extrapolated to infinity is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Digoxin)
hour * nanomole / liter (h*nmol/L)Digoxin (Period 1)Digoxin + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Digoxin)13.34 ± NA22.71 ± NA
Statistical analysis
  • Digoxin (Period 1) vs Digoxin + BI 730357 (Period 2) · Geometric means ratio: 170.29 · 90% CI 143.73 to 201.76The geometric means ratio was calculated as Digoxin + BI 730357 / Digoxin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryMaximum Measured Concentration of Metformin in Plasma (Cmax, Metformin)

Maximum measured concentration of Metformin in plasma is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · nanomole / liter (nmol/L)
Maximum Measured Concentration of Metformin in Plasma (Cmax, Metformin)
nanomole / liter (nmol/L)Metformin (Period 1)Metformin + BI 730357 (Period 2)
Maximum Measured Concentration of Metformin in Plasma (Cmax, Metformin)235.86 ± NA215.63 ± NA
Statistical analysis
  • Metformin (Period 1) vs Metformin + BI 730357 (Period 2) · Geometric means ratio: 91.42 · 90% CI 88.04 to 94.93The geometric means ratio was calculated as Metformin + BI 730357 / Metformin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryMaximum Measured Concentration of Rosuvastatin in Plasma (Cmax, Rosuvastatin)

Maximum measured concentration of Rosuvastatin in plasma is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · nanomole / liter (nmol/L)
Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax, Rosuvastatin)
nanomole / liter (nmol/L)Rosuvastatin (Period 1)Rosuvastatin + BI 730357 (Period 2)
Maximum Measured Concentration of Rosuvastatin in Plasma (Cmax, Rosuvastatin)6.92 ± NA9.63 ± NA
Statistical analysis
  • Rosuvastatin (Period 1) vs Rosuvastatin + BI 730357 (Period 2) · Geometric means ratio: 139.03 · 90% CI 124.29 to 155.51The geometric means ratio was calculated as Rosuvastatin + BI 730357 / Rosuvastatin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryMaximum Measured Concentration of Furosemide in Plasma (Cmax, Furosemide)

Maximum measured concentration of Furosemide in plasma is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Maximum Measured Concentration of Furosemide in Plasma (Cmax, Furosemide)
hour * nanomole / liter (h*nmol/L)Furosemide (Period 1)Furosemide + BI 730357 (Period 2)
Maximum Measured Concentration of Furosemide in Plasma (Cmax, Furosemide)51.03 ± NA57.21 ± NA
Statistical analysis
  • Furosemide (Period 1) vs Furosemide + BI 730357 (Period 2) · Geometric means ratio: 112.10 · 90% CI 101.26 to 124.11The geometric means ratio was calculated as Furosemide + BI 730357 / Furosemide. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
PrimaryMaximum Measured Concentration of Digoxin in Plasma (Cmax, Digoxin)

Maximum measured concentration of Digoxin in plasma is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · nanomole / liter (nmol/L)
Maximum Measured Concentration of Digoxin in Plasma (Cmax, Digoxin)
nanomole / liter (nmol/L)Digoxin (Period 1)Digoxin + BI 730357 (Period 2)
Maximum Measured Concentration of Digoxin in Plasma (Cmax, Digoxin)0.87 ± NA1.40 ± NA
Statistical analysis
  • Digoxin (Period 1) vs Digoxin + BI 730357 (Period 2) · Geometric means ratio: 161.29 · 90% CI 129.17 to 201.39The geometric means ratio was calculated as Digoxin + BI 730357 / Digoxin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
SecondaryArea Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Metformin)

Area under the concentration-time curve of Metformin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Metformin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Metformin)
hour * nanomole / liter (h*nmol/L)Metformin (Period 1)Metformin + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Metformin)1450.30 ± NA1424.70 ± NA
Statistical analysis
  • Metformin (Period 1) vs Metformin + BI 730357 (Period 2) · Geometric means ratio: 98.23 · 90% CI 94.86 to 101.73The geometric means ratio was calculated as Metformin + BI 730357 / Metformin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
SecondaryArea Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Rosuvastatin)

Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Rosuvastatin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h * nmol/L)
Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Rosuvastatin)
hour * nanomole / liter (h * nmol/L)Rosuvastatin (Period 1)Rosuvastatin + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Rosuvastatin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Rosuvastatin)78.83 ± NA93.54 ± NA
Statistical analysis
  • Rosuvastatin (Period 1) vs Rosuvastatin + BI 730357 (Period 2) · Geometric means ratio: 118.67 · 90% CI 108.83 to 129.40The geometric means ratio was calculated as Rosuvastatin + BI 730357 / Rosuvastatin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
SecondaryArea Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Furosemide)

Area under the concentration-time curve of Furosemide in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Furosemide in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Furosemide)
hour * nanomole / liter (h*nmol/L)Furosemide (Period 1)Furosemide + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Furosemide in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Furosemide)151.01 ± NA172.26 ± NA
Statistical analysis
  • Furosemide (Period 1) vs Furosemide + BI 730357 (Period 2) · Geometric means ratio: 114.07 · 90% CI 107.93 to 120.56The geometric means ratio was calculated as Furosemide + BI 730357 / Furosemide. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).
SecondaryArea Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Digoxin)

Area under the concentration-time curve of Digoxin in plasma over the time interval from 0 to the last quantifiable data point is reported. The geometric mean is actually adjusted geometric mean.

Time frame:
2 hours (h) before and at 20 minutes (min), 40min, 1h, 1h30min, 2h, 2h30min, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 71h, 95h after administration of Digoxin in both periods plus at 143h in period 1 and at 119h and 167h in period 2.
Reported as:
Geometric mean · hour * nanomole / liter (h*nmol/L)
Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Digoxin)
hour * nanomole / liter (h*nmol/L)Digoxin (Period 1)Digoxin + BI 730357 (Period 2)
Area Under the Concentration-time Curve of Digoxin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz, Digoxin)11.00 ± NA19.11 ± NA
Statistical analysis
  • Digoxin (Period 1) vs Digoxin + BI 730357 (Period 2) · Geometric means ratio: 173.77 · 90% CI 141.90 to 212.80The geometric means ratio was calculated as Digoxin + BI 730357 / Digoxin. Standard error of the mean is actually the intra-individual geometric coefficient of variation (gCV).

Adverse events

Collected over Cocktail: From 1st dose of cocktail until 1st dose of BI 730357 (BI) or end of 10 days residual effect period (REP) of cocktail, whichever occurs earlier, up to 10 days. Cocktail+BI: the period where the REP of the 1st dose of cocktail overlaps with the start of the dosing of BI, up to 3 days. BI: From 1st dose of BI or end of 10 days REP (whichever occurs later) until 2nd dose of cocktail, up to 7 days. BI+Cocktail: From 2nd dose of cocktail until last dose of BI+7 days of REP, up to 13 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cocktail (Period 1)0/15 (0%)0/15 (0%)6/15 (40%)
Cocktail+BI 730357 (Overlap Period)0/15 (0%)0/15 (0%)1/15 (6.7%)
BI 730357 (Period 2)0/15 (0%)0/15 (0%)4/15 (26.7%)
BI 730357+Cocktail (Period 2)0/14 (0%)0/14 (0%)4/14 (28.6%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCocktail (Period 1)Cocktail+BI 730357 (Overlap Period)BI 730357 (Period 2)BI 730357+Cocktail (Period 2)
HeadacheNervous system disorders5/150/150/152/14
ParosmiaNervous system disorders0/150/150/151/14
MalaiseGeneral disorders0/150/150/151/14
NasopharyngitisInfections and infestations0/150/150/151/14
Dry skinSkin and subcutaneous tissue disorders0/150/150/151/14
DizzinessNervous system disorders1/150/150/150/14
Back painMusculoskeletal and connective tissue disorders0/150/151/150/14
Pain in extremityMusculoskeletal and connective tissue disorders0/150/151/150/14
FatigueGeneral disorders1/150/151/150/14
Skin erosionSkin and subcutaneous tissue disorders1/150/150/150/14

Baseline characteristics

Treated set (TS): The treated set includes all subjects who signed informed consent and were treated with at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Cocktail (R) / BI 730357+Cocktail (T)
Mean34.2 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Cocktail (R) / BI 730357+Cocktail (T)
Female5
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cocktail (R) / BI 730357+Cocktail (T)
Hispanic or Latino1
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cocktail (R) / BI 730357+Cocktail (T)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White15
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: http://trials.boehringer-ingelheim.com/

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jan 2021, 2 months.

Results were first posted in Jul 2023, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2020
First posted
Oct 19, 2020
StartActual
Oct 20, 2020
Primary completionActual
Jan 11, 2021
CompletionActual
Jan 11, 2021
Results first posted
Jul 17, 2023
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04590937
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Oct 20, 2020
Primary completion
Jan 11, 2021
Completion
Jan 11, 2021
Results posted
Jul 17, 2023
Last update
Sep 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevurogant · Rosuvastatin · Digoxin · Metformin · Furosemide

Start the discussion